Maravai (MRVI) Insider Award: 89k RSUs Added to Beneficial Ownership

Rhea-AI Filing Summary

Maravai LifeSciences Holdings, Inc. (MRVI) – Form 4 insider filing dated 06/18/2025

Director Benjamin James Daverman reported the acquisition of 89,139 Class A common-stock restricted stock units (RSUs) on 06/16/2025 under the company’s 2020 Omnibus Incentive Plan. The RSUs were recorded at an accounting grant price of $2.16 per share and will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual meeting of stockholders.

Following this grant, Daverman’s reported beneficial ownership rises to 138,055 shares, classified as direct ownership. However, the filing notes that these securities are held for the benefit of a GTCR-affiliated entity; Daverman disclaims any pecuniary interest, a standard practice for partners of private-equity sponsors serving on portfolio-company boards.

No derivative securities were reported in Table II, and there were no dispositions. The transaction was filed by one reporting person, and the box indicating Rule 10b5-1(c) trading-plan activity was not checked, implying the RSU grant was a standard board-compensation award.

Key take-aways for investors:

• The award helps align director incentives with shareholder value through equity compensation.
• Because the shares are RSUs (not an open-market purchase), the grant does not directly signal insider conviction about current valuation.
• The relatively modest share count and beneficial-ownership disclosure are unlikely to materially affect MRVI’s share float or governance structure.

Positive

• Equity-based compensation aligns director incentives with shareholder interests through 89,139 RSUs.
• Short vesting horizon (one year or earlier AGM) promotes near-term engagement by the director.

Negative

• Economic interest is disclaimed in favor of GTCR, limiting the signal value for outside investors.
• Grant is non-cash and non-open-market, providing no direct indication of insider conviction regarding MRVI’s valuation.

Insights

Financial Analyst

TL;DR: Routine RSU grant; incremental alignment, limited market impact.

The 89,139-share RSU award represents a small fraction of Maravai’s outstanding shares and appears to be standard annual board compensation. Vesting over one year keeps the director engaged but, given the disclaimer of pecuniary interest for GTCR, the economic signal is muted. No cash outlay or open-market activity occurred, so dilution is de minimis and investor perception should be neutral to slightly positive due to incentive alignment. I do not expect material valuation impact.

Corporate Governance Expert

TL;DR: Governance-friendly RSU structure; ownership benefits GTCR, not individual.

Granting equity to non-employee directors is best practice, and the one-year cliff or earlier AGM vesting mirrors typical governance standards. The disclaimer clarifies fiduciary alignment with GTCR, reducing personal enrichment concerns. Because shares are held for a private-equity sponsor, actual voting control does not change. The filing contains no red flags but likewise offers little directional insight for public investors.

Insider Trade Summary

Net Buyer: 89,139 shares

Net Buy 1 txn

Insider DAVERMAN BENJAMIN JAMES

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	89,139	$2.16	$193K

Holdings After Transaction: Class A Common Stock — 138,055 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
2. F2. The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/18/2025 - 06:25 PM Learn about SEC filing dates

FAQ

How many Maravai (MRVI) shares did Director Benjamin Daverman acquire?

He received 89,139 restricted stock units on 06/16/2025.

What was the grant price of the RSUs reported in the Form 4?

The filing lists an accounting price of $2.16 per share.

When do the newly granted MRVI RSUs vest?

They vest in full on the earlier of one year from grant or the 2026 annual meeting.

How many MRVI shares does the insider own after the transaction?

Daverman’s reported beneficial ownership is now 138,055 shares.

Does the insider personally benefit economically from these shares?

The shares are held for a GTCR-affiliated entity; Daverman disclaims personal pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DAVERMAN BENJAMIN JAMES

(Last) (First) (Middle)

C/O GTCR, LLC

300 N. LASALLE SUITE 5600

(Street)

CHICAGO IL 60654

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		A		89,139(1)	A	$2.16	138,055(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

2. The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Benjamin Daverman	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.